MBOT icon

Microbot Medical

1.82 USD
+0.18
10.98%
At close Jan 21, 4:00 PM EST
After hours
1.85
+0.03
1.65%
1 day
10.98%
5 days
0.00%
1 month
87.61%
3 months
82.80%
6 months
71.70%
Year to date
59.65%
1 year
40.00%
5 years
-84.60%
10 years
-99.89%
 

About: Microbot Medical Inc is a pre-clinical medical device company. It specializes in developing next-generation micro-robotic medical technologies that can change the future of medicine. Their vision is to improve the quality of life of millions of patients globally by advancing micro-robotic technologies to perform surgical procedures and offer physicians and their patients less invasive and more precise solutions. The company's innovative platforms LIBERTY and Self-Cleaning Shunt (SCS) are in one of the fastest-growing segments in healthcare. The group continuously develops its technology with the goal to improve surgical outcomes worldwide. The firm presently holds domestic and global patents that strengthen its product portfolio and create barriers of entry.

Employees: 22

0
Funds holding %
of 6,823 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.48% less ownership

Funds ownership: 6.8% [Q2] → 6.33% (-0.48%) [Q3]

16% less capital invested

Capital invested by funds: $1.11M [Q2] → $933K (-$175K) [Q3]

29% less funds holding

Funds holding: 35 [Q2] → 25 (-10) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

75% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 12

Research analyst outlook

We haven’t received any recent analyst ratings for MBOT.

Financial journalist opinion

Based on 3 articles about MBOT published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Microbot Medical Closes $8.6 Million Registered Direct Offering
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company's common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter.
Microbot Medical Closes $8.6 Million Registered Direct Offering
Neutral
GlobeNewsWire
2 weeks ago
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 4,000,001 shares of the Company's common stock at a purchase price of $1.75 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered short-term series G preferred investment options. The short-term series G preferred investment options to purchase up to 8,000,002 shares of common stock have an exercise price of $1.75 per share and are immediately exercisable following issuance for a period of two years thereafter.
Microbot Medical Raises a Total of Approximately $11.8 Million in Gross Proceeds from Registered Direct Offering and Previously Announced ATM Facility
Neutral
GlobeNewsWire
3 weeks ago
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Positive
Zacks Investment Research
1 month ago
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
MBOT Stock Gains Following FDA Submission of the LIBERTY System
Neutral
GlobeNewsWire
1 month ago
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
Positive
Zacks Investment Research
3 months ago
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
Neutral
GlobeNewsWire
3 months ago
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully completed enrollment and follow up for all patients in its ACCESS-PVI human clinical trial.
Microbot Medical Announces the Successful Completion of its Pivotal Human Clinical Trial; Accelerates Go-to-Market Strategy to Prepare for Commercial Launch of LIBERTY® during 2Q 2025
Neutral
GlobeNewsWire
3 months ago
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it is currently experiencing an acceleration of patient enrollment for ACCESS-PVI human clinical trial for LIBERTY®.
Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up
Neutral
GlobeNewsWire
4 months ago
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Positive
Zacks Investment Research
4 months ago
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
Charts implemented using Lightweight Charts™